YOU ARE HERE:
Fusion inhibitors
T-20
Names: T-20, enfuvirtide, Fuzeon™
Approved dosage: 90mg (one injection under the skin) twice a day. The drug has to be made up from powder.
Tips on taking it: extensive support and advice is available to people prescribed T-20. Doses can be prepared within 24 hours of use, so two doses can be prepared together. T-20 can be injected into the thigh, arm or abdomen. A different injection site should be used each day to reduce problems with injection site reactions.
Common side-effects: injection site reaction, possibly involving an itchy rash, swollen red or puffy skin, hardening of the skin, or cysts.
Rare side-effects: abscesses at the injection site. Headache, difficulty sleeping. Increased risk of bacterial pneumonia. Rare hypersensitivity reaction involving difficulty breathing, fever, chills, skin rash and low blood-pressure.
Resistance to T-20: test-tube studies suggest that resistance to T-20 does not cause resistance to the experimental entry inhibitor T-1249. People who are resistant to T-20 may still get some benefit from it.
Key drug interactions: no significant interactions recorded.
Names: T-20, enfuvirtide, Fuzeon™
Approved dosage: 90mg (one injection under the skin) twice a day. The drug has to be made up from powder.
Tips on taking it: extensive support and advice is available to people prescribed T-20. Doses can be prepared within 24 hours of use, so two doses can be prepared together. T-20 can be injected into the thigh, arm or abdomen. A different injection site should be used each day to reduce problems with injection site reactions.
Common side-effects: injection site reaction, possibly involving an itchy rash, swollen red or puffy skin, hardening of the skin, or cysts.
Rare side-effects: abscesses at the injection site. Headache, difficulty sleeping. Increased risk of bacterial pneumonia. Rare hypersensitivity reaction involving difficulty breathing, fever, chills, skin rash and low blood-pressure.
Resistance to T-20: test-tube studies suggest that resistance to T-20 does not cause resistance to the experimental entry inhibitor T-1249. People who are resistant to T-20 may still get some benefit from it.
Key drug interactions: no significant interactions recorded.